Register for OBR daily

To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

CALA $2.85 0.3000 +11.76%
CYTK $9.74 0.9100 +10.31%
SNY $38.84 1.5900 +4.27%
LBIO $6.25 0.2500 +4.17%
MACK $5.30 0.1800 +3.52%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

GTXI $0.75 -0.0800 -9.64%
AMGN $145.18 -15.3900 -9.58%
MNKD $0.45 -0.0396 -8.08%
ALDR $24.80 -2.0000 -7.46%
MRTX $5.10 -0.4000 -7.27%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | Next > | Last >>

New Leadership Elected to American Society of Hematology

(ASH) Oct 26, 2016 - The American Society of Hematology (ASH), the world’s largest professional society concerned with the causes and treatment of blood disorders, today announced the election of four new members to its Executive Committee for terms beginning after the 2016 ASH Annual Meeting December 3-6 in San Diego.
read press release 

How Can Practices Seek Success With Oncology Payment Reform?

(AJMC) Oct 25, 2016 - At the Payer Exchange Summit V, sponsored by the Community Oncology Alliance (COA), held October 24-25, 2016, in Tyson’s Corner, Virginia, Bruce Gould, MD, medical director, Northwest Georgia Oncology Center, presented an overview of how cancer care has improved over the years, what the challenges are, and how practices can adapt to payment reform.
read article 

New Website to Help Cancer Survivors Manage Health

(ACS) Oct 26, 2016 - The American Cancer Society and the National Cancer Institute have launched an easy-to-use website to help cancer survivors during and after cancer treatment.
read press release 

Access 2015 PQRS and QRUR Reports to Determine 2017 Payment Adjustments for Your Practice

(ASCO in Action) Oct 25, 2016 - In late September, the Centers for Medicare and Medicaid Services (CMS) released the 2015 Physician Quality Reporting System (PQRS) Feedback Reports and 2015 Annual Quality and Resource Use Reports (QRURs). These reports are used to determine whether a practice will receive bonuses or be subject to PQRS and Value Modifier payment penalties in 2017.
read article 

Novartis Looks at Up to $5 Billion Deals in Cancer, Generics

(Bloomberg/Markets blog) Oct 25, 2016 - Novartis AG, Europe’s second-biggest drugmaker by sales, said it’s looking for acquisitions that cost between $2 billion and $5 billion to bolster its position in areas including cancer and the development of copycat medicines.
read article 

Strategies for OCM Implementation at the COA Payer Summit

(AJMC) Oct 25, 2016 - What are some of the challenges that clinical practices will face as they implement the Medicare Oncology Care Model (OCM)? What are some of the strategies that have worked for practices using similar payment models?
read article 

Terminally Ill Cancer Patients Fare Poorly After Surgery

(UC Davis Health System) Oct 25, 2016 - Patients with disseminated advanced cancer who undergo surgery are far more likely to endure long hospital stays and readmissions, referrals to extended care facilities and death, UC Davis researchers have found.
read press release 

IU Research Reveals Link Between Molecular Mechanisms in Prostate Cancer and Ewing's Sarcoma

(Indiana University) Oct 25, 2016 - Medical researchers at Indiana University Bloomington have found evidence for a link between prostate cancer, which affects millions of men age 50 and older, and Ewing's sarcoma, a rare form of cancer that affects children and young adults.
read press release 

Fat in Feces Points to Early Presence of Colorectal Cancer

(WSU News) Oct 25, 2016 - Scientists at Washington State University and Johns Hopkins Medical School have discovered a fast, noninvasive method that could lead to the early diagnosis of colorectal cancer.
read article 

Nonsurgical Treatment of Rectal Cancer Questioned

(MedPage Today) Oct 25, 2016 - Nonsurgical management of nonmetastatic rectal cancer led to worse survival compared with upfront surgery, a retrospective review of a national database showed, contradicting data from several recent studies.
read article (free registration required) 

Myriad's BRACAnalysis CDx® Test Identifies Patients with Ovarian Cancer Who Would Benefit From Second-Line Maintenance Treatment with Olaparib

(Myriad Genetics) Oct 26, 2016 - Myriad Genetics, Inc., a leader in molecular diagnostics and personalized medicine, today announced that its BRACAnalysis CDx® test accurately identified patients who may benefit from treatment with olaparib. The BRACAnalysis CDx test was included in the SOLO2 study (NCT01874353) as a diagnostic with olaparib, an oral PARP inhibitor being developed by AstraZeneca.
read corporate press release 

OncoGenex Announces Positive Survival Results From Apatorsen Phase 2 Borealis-2™ Trial in Metastatic Bladder Cancer

(OncoGenex) Oct 25, 2016 - OncoGenex Pharmaceuticals, Inc. announced today positive survival results from the final analysis of the Phase 2 Borealis-2™ trial of apatorsen in combination with docetaxel treatment that enrolled 200 patients with metastatic bladder cancer whose disease had progressed following first-line platinum-based chemotherapy.
read corporate press release 

LYNPARZATM (olaparib) Phase III SOLO-2 Trial Shows Significant Progression-Free Survival Benefit

(StreetInsider) Oct 26, 2016 - AstraZeneca today announced positive results from the Phase III SOLO-2 trial designed to determine the efficacy of LYNPARZATM (olaparib) tablets (300mg twice daily) as a monotherapy for the maintenance treatment of platinum-sensitive relapsed, BRCA-mutated ovarian cancer.
read article 

Rates Up 22 Percent For Obamacare Plans, But Subsidies Rise, Too

(NPR/Shots blog) Oct 24, 2016 - The cost of health insurance under the Affordable Care Act is expected to rise an average of 22 percent in 2017, according to information released by the Obama administration Monday afternoon.
read article 

Novartis CEO Sees Tougher U.S. Drug Pricing over next Three-Five Years

(Reuters) Oct 25, 2016 - Novartis expects a more difficult pricing environment for drugs in the United States in the years ahead, its chief executive told a results conference call on Tuesday.
read article 

AARP Sues U.S. Agency Over Employee Wellness Programs

(Reuters) Oct 24, 2016 - A lobbying group representing older Americans sued the Obama administration on Mondayclaiming regulations for programs designed to rein in employee health care costs will subject workers to invasions of their medical privacy.
read article 

Approving a Problematic Muscular Dystrophy Drug

(JAMA) Oct 24, 2016 - In September 2016, the US Food and Drug Administration (FDA) approved eteplirsen (Exondys 51), a new drug for Duchenne muscular dystrophy (DMD), overruling the recommendations of both its scientific staff and its external advisory committee.
read article 

Caris Life Sciences and Threshold Pharmaceuticals Collaborate to Utilize Caris’ ADAPT Biotargeting System in the Development Program for Evofosfamide

(Yahoo! Finance) Oct 25, 2016 - Caris Life Sciences, a leading biotechnology company focused on fulfilling the promise of precision medicine, and Threshold Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company specializing in the development of novel pharmaceutical products for the treatment of cancer, today announced that they have entered into a development and commercialization agreement to utilize Caris’ patented and proprietary ADAPT Biotargeting System™ to develop a tissue-based clinical diagnostic assay for pancreatic cancer patients to predict the likelihood of response to evofosfamide, Threshold’s lead drug candidate for the potential treatment of patients with cancer.
read article 

CMS to Host Webinars on Final MACRA Rule

(ACCC) Oct 24, 2016 - The Centers for Medicare & Medicaid Services (CMS) is hosting a series of webinars on the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) final rule with comment period. These webinars will provide an overview of the Merit-based Incentive Payment System (MIPS) and Advanced Alternative Payment Model (APM) incentive payment provisions under MACRA, collectively referred to as the Quality Payment Program.
read article 

Cancer Care: Is World Class Status a Distant Dream?

(BBC News) Oct 24, 2016 - Linear accelerators are wonderful machines. They deliver high-energy radiation to a tumour, helping to destroy cancer cells while sparing the normal tissue which surrounds them.
read article 

ASCO Recommends Key Priorities for 21st Century Cures

(ASCO in Action) Oct 24, 2016 - ASCO sent a letter to leaders in the U.S. House of Representatives and the U.S. Senate applauding the bipartisan, bicameral work to advance the 21st Century Cures Act, and urging leaders to move the bill through final passage when Congress returns into session later this year.
read article 

IBM CEO On Watson's Latest Answers For Fighting Cancer

(CBS News) Oct 24, 2016 - IBM CEO Ginni Rometty is convinced we are in the “third era of technology,” as IBM’s Watson Health partners with Quest Diagnostics to offer its cognitive computing technology nationwide for the first time.
read article 

Agilent Technologies Receives Expanded FDA Approval for Use of Dako PD-L1 IHC 22C3 pharmDx Companion Diagnostic in Non-Small Cell Lung Cancer (NSCLC)

(Agilent) Oct 24, 2016 - Agilent Technologies Inc. today announced that its Dako PD-L1 IHC 22C3 pharmDx now has an expanded label approved by the U.S. Food and Drug Administration for use in determining PD-L1 expression status to inform treatment in metastatic non-small cell lung cancer (NSCLC) with KEYTRUDA® (pembrolizumab).
read press release 

DINO RNA Molecule Triggers Anticancer Response in Damaged Cells

(NCI Cancer Currents Blog) Oct 24, 2016 - Researchers from Stanford University have identified an important molecule involved in the process that normally causes irreparably damaged cells to self-destruct.
read article 

Cancer Risk Reduction in the Trenches: PCPs Respond

(Medscape Medical News) Oct 25, 2016 - Cancer is often cited as the disease most Americans fear, and the latest statistics from the National Cancer Institute show that it will affect more than 1 in 3 people (39%).
read article